Aceclofenac is an anti-rheumatic and non-steroidal anti-inflammatory medicine (NSAID) utilized to cure
an extensive assortment of painful conditions (e.g., arthritis, gout, lupus, sciatica, back pain, traumatic
pain, gynecological pain, etc.) with minimal and infrequent adverse effects. Its biological half-life,
however, is only 4–4.3 h. So, to have a longer-lasting effect, you need medication with a controlled
release. Aceclofenac requires a loading dosage of a lower dose and a maintenance dose of a higher dose.
Since its therapeutic effect can be extended by using sustained-release matrix tablets, it is a medication of
choice for this purpose. In the current research, hydrophilic polymers (HPMC, Carobopol 940) were
utilized to prepare and evaluate matrix tablets of aceclofenac, in the hope of achieving sustained drug
release after a single dose has been given, hence extending the drug's therapeutic effect. The FTIR
analysis showed that the medicine is completely compatible with all of the excipients used in the
formulation. This approach of direct compression was preferred to create the tablets. The tablets were
examined for hardness, thickness, weight fluctuation, Content Uniformity, friability, swelling index, and
in-vitro release. All of the tablets had qualities that could be considered satisfactory. With an average G.I.
residence length of 10–12 hours, our matrix formulation containing [HPMC and Carbopol 940 (75:25)] is
possibly demonstrating superior release.
Keywords: NSAID; Matrix tablets; Aceclofenac; HPMC; Carbopol 940
Publication date: 01/09/2023
https://ijbpas.com/pdf/2023/September/MS_IJBPAS_2023_7397.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.9.7397
